TABLE II.
Severe (n = 39) | Mild-to-moderate (n = 36) | P | |
---|---|---|---|
Age (y) | 10 (6–17) | 10 (6–15) | .119 |
Ethnicity | |||
White | 9 (23%) | 26 (72%) | .000 |
African American | 27 (69%) | 7 (19%) | |
Other | 3 (8%) | 3 (8%) | |
Male | 21 (54%) | 18 (50%) | .459 |
Female | 18 (46%) | 18 (50%) | |
Age at diagnosis (mo) | 22 (2–144) | 60 (2–156) | .000 |
Daily daytime symptoms† | 19 (49%) | 6 (17%) | .007 |
Daily nocturnal symptoms | 11 (28%) | 0 | .030 |
Atopic dermatitis | 27 (69%) | 15 (42%) | .021 |
Immediate family history of asthma | 31 (79%) | 19 (53%) | .027 |
Total hospital admissions | 4 (0–25) | 0 (0–3) | .000 |
Total intensive care unit admissions | 1 (0–10) | 0 (0–1) | .000 |
Daily medications | |||
Short-acting β-agonists‡ | 22 (56%) | 3 (8%) | .000 |
Long-acting β-agonists§ | 33 (85%) | 23 (64%) | .000 |
Montelukast (Merck, Whitehouse Station, NJ) | 39 (100%) | 23 (64%) | .041 |
Prednisone | 8 (21%) | 0 |
Values represent the frequency (percentage) or the median (range).
Six subjects with mild-to-moderate asthma experienced bronchospasm with daily participation in organized sports.
Three subjects with mild-to-moderate asthma used prophylactic β-agonists before daily sports participation.
All children with long-acting β-agonist use were on fluticasone/salmeterol combination therapy.